IL300586A - SARM1 inhibitors - Google Patents

SARM1 inhibitors

Info

Publication number
IL300586A
IL300586A IL300586A IL30058623A IL300586A IL 300586 A IL300586 A IL 300586A IL 300586 A IL300586 A IL 300586A IL 30058623 A IL30058623 A IL 30058623A IL 300586 A IL300586 A IL 300586A
Authority
IL
Israel
Prior art keywords
ring
nitrogen
compound
compound according
sulfur
Prior art date
Application number
IL300586A
Other languages
English (en)
Hebrew (he)
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of IL300586A publication Critical patent/IL300586A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL300586A 2020-08-24 2021-08-23 SARM1 inhibitors IL300586A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US202163142398P 2021-01-27 2021-01-27
PCT/US2021/047093 WO2022046606A1 (en) 2020-08-24 2021-08-23 Inhibitors of sarm1

Publications (1)

Publication Number Publication Date
IL300586A true IL300586A (en) 2023-04-01

Family

ID=77775005

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300586A IL300586A (en) 2020-08-24 2021-08-23 SARM1 inhibitors

Country Status (18)

Country Link
US (2) US12043613B2 (enExample)
EP (1) EP4200293A1 (enExample)
JP (2) JP7349046B2 (enExample)
KR (1) KR20230057396A (enExample)
AU (2) AU2021333558C1 (enExample)
BR (1) BR112023002575A2 (enExample)
CA (1) CA3189181A1 (enExample)
CL (1) CL2023000525A1 (enExample)
CO (1) CO2023001975A2 (enExample)
CR (1) CR20230113A (enExample)
DO (1) DOP2023000038A (enExample)
EC (1) ECSP23012981A (enExample)
IL (1) IL300586A (enExample)
MX (1) MX2023002256A (enExample)
PE (1) PE20230737A1 (enExample)
TW (2) TW202334117A (enExample)
WO (1) WO2022046606A1 (enExample)
ZA (1) ZA202301801B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
WO2022031736A1 (en) 2020-08-04 2022-02-10 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
CN120456910A (zh) * 2022-07-21 2025-08-08 艾美力克斯制药股份有限公司 寡核苷酸组合物及其方法
WO2024125624A1 (en) * 2022-12-15 2024-06-20 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
CN121002009A (zh) 2023-01-24 2025-11-21 达萨玛治疗公司 作为sarm1抑制剂的哒嗪类物
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンa3受容体拮抗剤およびチアゾール化合物
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
ATE466855T1 (de) 2002-10-30 2010-05-15 Vertex Pharma Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
EP1581222A2 (en) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
JP2008524233A (ja) 2004-12-16 2008-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 炎症性疾患、増殖性疾患および免疫介在性疾患の治療のためのtecファミリータンパク質キナーゼのインヒビターとして有用なピリド−2−オン
CN101472921B (zh) 2006-06-28 2012-10-10 Aska制药株式会社 吡啶基异*唑衍生物
US20100105664A1 (en) 2006-09-21 2010-04-29 Richard Heng Organic compounds
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Pi3キナーゼ阻害剤として用いられるチアゾール誘導体
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
US20120328629A1 (en) 2011-06-24 2012-12-27 University Of Miami Therapeutic Applications Targeting SARM1
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
EP2934536B1 (en) 2012-12-19 2017-09-27 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
EP3076789A4 (en) 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
UY37512A (es) 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
JP2020503312A (ja) * 2016-12-22 2020-01-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換1,2,4−チアジアゾリルピロロンおよび1,2,4−チアジアゾリルヒダントイン、ならびにその塩、ならびにその除草剤としての使用
EP3558976A1 (de) 2016-12-22 2019-10-30 Bayer CropScience Aktiengesellschaft Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
AU2018388406B2 (en) * 2017-12-22 2023-07-06 HiberCell Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
MA52812A (fr) * 2018-06-07 2021-04-14 Disarm Therapeutics Inc Inhibiteurs de sarm1
MA52809A (fr) 2018-06-07 2021-04-14 Disarm Therapeutics Inc Inhibiteurs de sarm1
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
US12084436B2 (en) 2019-01-30 2024-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7289375B2 (ja) 2019-06-06 2023-06-09 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CA3141404A1 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021013721A1 (de) 2019-07-22 2021-01-28 Bayer Aktiengesellschaft 5-amino substituierte pyrazole und triazole als schädlingsbekämpfungsmittel
CA3150878A1 (en) 2019-09-12 2021-03-18 Jonathan Bentley Inhibitors of sarm1
AU2020380395A1 (en) 2019-11-05 2022-05-26 Dermira, Inc. MrgprX2 antagonists for the treatment of inflammatory disorders
JP7490781B2 (ja) 2020-01-07 2024-05-27 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CN116075511B (zh) 2020-04-09 2024-10-29 达萨玛治疗公司 作为sarm1抑制剂的稠合吡唑衍生物
ES3049432T3 (en) 2020-04-09 2025-12-16 Disarm Therapeutics Inc Indazole derivatives as inhibitors of sarm1
WO2022031736A1 (en) 2020-08-04 2022-02-10 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors

Also Published As

Publication number Publication date
MX2023002256A (es) 2023-03-17
KR20230057396A (ko) 2023-04-28
AU2021333558A1 (en) 2023-03-02
AU2021333558C1 (en) 2024-06-20
CO2023001975A2 (es) 2023-03-07
US20220056013A1 (en) 2022-02-24
JP2023535236A (ja) 2023-08-16
US20240376083A1 (en) 2024-11-14
JP7349046B2 (ja) 2023-09-21
JP7756130B2 (ja) 2025-10-17
TW202214597A (zh) 2022-04-16
ZA202301801B (en) 2024-09-25
TWI786777B (zh) 2022-12-11
EP4200293A1 (en) 2023-06-28
CL2023000525A1 (es) 2023-09-15
AU2021333558B2 (en) 2024-02-22
CR20230113A (es) 2023-04-14
AU2024203373A1 (en) 2024-06-13
ECSP23012981A (es) 2023-03-31
WO2022046606A1 (en) 2022-03-03
TW202530197A (zh) 2025-08-01
US12043613B2 (en) 2024-07-23
CA3189181A1 (en) 2022-03-03
BR112023002575A2 (pt) 2023-03-07
DOP2023000038A (es) 2023-03-15
PE20230737A1 (es) 2023-05-03
JP2024016014A (ja) 2024-02-06
TW202334117A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
IL300586A (en) SARM1 inhibitors
US12331033B2 (en) Inhibitors of SARM1
JP7319395B2 (ja) Sarm1の阻害剤
EP4132920B1 (en) Indazole derivatives as inhibitors of sarm1
EP4132928B1 (en) Condensed pyrazole derivatives as inhibitors of sarm1
JP7746384B2 (ja) Sarm1のベンゾピラゾール阻害剤
JP2022547707A (ja) Sarm1の阻害剤
EA048703B1 (ru) Ингибиторы sarm1
BR122025022748A2 (pt) Inibidores de sarm1, composições que os compreendem, usos dos mesmos, métodos para inibir sarm1, e combinações
CN116940569A (zh) Sarm1抑制剂